Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer (DL38835)

This document is a response to public comments on the MolDX LCD DL38835 (Minimal Residual Disease Testing for Cancer). It records the comment period (10/01/2021–11/14/2020), notice period start (11/11/2021), and effective date (12/26/2021) but does not specify clinical coverage criteria, limitations, documentation requirements, or frequency limits.